february, 2018

01feb8:00 am10:00 amNASH: A Silent Epidemic Poised to Swamp the BioPharma Industry?


Event Details

With our panel of diverse thought leaders we will strategically explore the following questions:

  • What is the unmet need in NASH?
  • How is the treatment landscape evolving and what does the future of NASH hold?
  • Why is NASH of such high interest to the pharma/biotech space?
  • What are the implications to the healthcare system if new NASH therapies are approved? – Who will treat? Who will be treated? Who will pay?
  • What does a pharma company need to do to shape the market and achieve a lasting impact in the space?
  • What are the pricing analogies (e.g. Sovaldi) that might help prepare a biopharma company for successful commercialization?


  • Jagpreet Chhatwal, PhD, Assistant Professor, Harvard Medical School, Senior Scientist, MGH Institute for Technology Assessment
  • Rosana Kapeller, MD, PhD, Chief Scientific Officer, Nimbus Therapeutics
  • Raza Malik, MD, PhD, FRCP, Medical Director, Hepatology & Hepatobiliary Program, Beth Israel Deaconess Medical Center, Harvard Medical School


  • Amama Sadiq, MD, MPH, Medical Director, Clarion Healthcare


(Thursday) 8:00 am - 10:00 am


Broad Institute

415 Main Street, Cambridge MA